专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006046683A1 THIAZOLYLBENZOFURAN DERIVATIVES AS LEUKOTRIENE AND PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS 审中-公开
标题翻译：噻吗啉衍生物作为白介素和前列腺素D2受体拮抗剂
公开(公告)号：WO2006046683A1
公开(公告)日：2006-05-04
申请号：PCT/JP2005/019854
申请日：2005-10-24
申请人： ASTELLAS PHARMA INC. , SHIGENAGA, Shinji , HIGUCHI, Koichi , MUKOYOSHI, Koichiro , TANABE, Daisuke , INOUE, Takayuki , SATO, Kentaro , TENDA, Yoshiyuki , TSUJIMOTO, Susumu
发明人： SHIGENAGA, Shinji , HIGUCHI, Koichi , MUKOYOSHI, Koichiro , TANABE, Daisuke , INOUE, Takayuki , SATO, Kentaro , TENDA, Yoshiyuki , TSUJIMOTO, Susumu
IPC分类号： C07D417/14 , A61K31/425
CPC分类号： C07D417/14
摘要： There is provided a compound of the formula (I): wherein R 1 is lower alkyl, R 2 is lower alkyl substituted with a substituent selected from the group consisting of carboxy and esterified carboxy, and R 3 is lower alkoxy substituted with lower alkylcarbamoyl, or a pharmaceutically acceptable salt thereof, which are useful as a medicament.
摘要翻译：提供式（I）化合物：其中R 1为低级烷基，R 2为被选自下组的取代基取代的低级烷基：羧基和酯化的羧基，R 3是用作药物的低级烷基氨基甲酰基或其药学上可接受的盐取代的低级烷氧基。

2. 发明申请

WO2007077949A1 HETEROCYCLIC JANUS KINASE 3 INHIBITORS 审中-公开
标题翻译：杂交种JANUS KINASE 3抑制剂
公开(公告)号：WO2007077949A1
公开(公告)日：2007-07-12
申请号：PCT/JP2006/326327
申请日：2006-12-25
申请人： ASTELLAS PHARMA INC. , INOUE, Takayuki , TANAKA, Akira , NAKAI, Kazuo , SASAKI, Hiroshi , TAKAHASHI, Fumie , SHIRAKAMI, Shohei , HATANAKA, Keiko , NAKAJIMA, Yutaka , MUKOYOSHI, Koichiro , HAMAGUCHI, Hisao , KUNIKAWA, Shigeki , HIGASHI, Yasuyuki
发明人： INOUE, Takayuki , TANAKA, Akira , NAKAI, Kazuo , SASAKI, Hiroshi , TAKAHASHI, Fumie , SHIRAKAMI, Shohei , HATANAKA, Keiko , NAKAJIMA, Yutaka , MUKOYOSHI, Koichiro , HAMAGUCHI, Hisao , KUNIKAWA, Shigeki , HIGASHI, Yasuyuki
IPC分类号： C07D471/04 , C07D471/14 , A61P37/06 , A61P11/06 , A61P17/00 , A61P25/28 , A61P35/00 , A61P35/02 , A61K31/437 , C07D451/04
CPC分类号： C07D451/04 , C07D471/04 , C07D471/14 , C07D519/00
摘要： The present invention provides a compound of formula (I) having an excellent JAK3 inhibition activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases inflammatory diseases, and allergic diseases. The compound according to the present invention has an inhibition activity against JAK3 and is thus useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transmission (e.g., rejection during organ/tissue transplantation, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, Alzheimer's disease, and atherosclerotic disease), or diseases caused by abnormal cytokine signal transmission (e.g., cancer and leukemia).
摘要翻译：本发明提供具有优异的JAK3抑制活性的式（I）化合物，并且可用作治疗和/或预防各种免疫疾病，包括自身免疫性疾病炎性疾病和过敏性疾病的药剂的活性成分。根据本发明的化合物对JAK3具有抑制活性，因此可用作治疗或预防由不良细胞因子信号传导引起的疾病（例如器官/组织移植期间的排斥，自身免疫性疾病，多发性硬化症）的活性成分，类风湿性关节炎，牛皮癣，哮喘，特应性皮炎，阿尔茨海默病和动脉粥样硬化疾病）或由异常细胞因子信号传导引起的疾病（例如癌症和白血病）。

3. 发明申请

WO2007007919A2 NOVEL COMPOUNDS 审中-公开
标题翻译：新型化合物
公开(公告)号：WO2007007919A2
公开(公告)日：2007-01-18
申请号：PCT/JP2006/314326
申请日：2006-07-13
申请人： ASTELLAS PHARMA INC. , INOUE, Takayuki , TOJO, Takashi , MORITA, Masataka , NAKAJIMA, Yutaka , HATANAKA, Keiko , SHIRAKAMI, Shohei , SASAKI, Hiroshi , TANAKA, Akira , TAKAHASHI, Fumie , MUKOYOSHI, Koichiro , HIGASHI, Yasuyuki , OKIMOTO, Akira , HONDO, Takeshi , SAWADA, Hitoshi
发明人： INOUE, Takayuki , TOJO, Takashi , MORITA, Masataka , NAKAJIMA, Yutaka , HATANAKA, Keiko , SHIRAKAMI, Shohei , SASAKI, Hiroshi , TANAKA, Akira , TAKAHASHI, Fumie , MUKOYOSHI, Koichiro , HIGASHI, Yasuyuki , OKIMOTO, Akira , HONDO, Takeshi , SAWADA, Hitoshi
IPC分类号： C07D471/04 , C07D471/14 , C07D498/04 , A61P37/06 , A61P11/06 , A61P17/00 , A61P25/28 , A61P35/00 , A61P35/02 , A61K31/437
CPC分类号： C07D471/14 , C07D519/00
摘要： The invention relates to compound of the formula (I) or its salt, wherein -R 1 , -R 2 , -R 3 , -R 4 , -R 5 , -M-, -X- and -Y= are as defined in the description, their use of as, medicament, the process for their preparation and use for the treatment of JAK3 mediated diseases.
摘要翻译：本发明涉及式（I）化合物或其盐，其中-R 1，R 2，R 3， R 4，-R 5，-M-，-X-和-Y =如说明书中所定义的，它们作为药物的用途为它们的制备和用于治疗JAK3介导的疾病。

4. 发明申请

WO2006028269A2 THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY 审中-公开
标题翻译：具有VAP-1抑制活性的噻唑衍生物
公开(公告)号：WO2006028269A2
公开(公告)日：2006-03-16
申请号：PCT/JP2005/016984
申请日：2005-09-08
申请人： Astellas Pharma Inc. , INOUE, Takayuki , TOJO, Takashi , MORITA, Masataka
发明人： INOUE, Takayuki , TOJO, Takashi , MORITA, Masataka
IPC分类号： C07D417/06 , A61K31/427 , A61P27/02 , C07D277/46 , A61K31/426 , C07D417/10 , C07D417/12
CPC分类号： C07D417/10 , C07D277/46 , C07D417/06 , C07D417/12
摘要： A compound of the formula (I): U-V-W-X-Y-Z (I) wherein U is lower alkyl; V is -CONH- or -NR 1 CO- wherein R 1 is a hydrogen or lower alkyl; W is a bond or lower alkylene; X is a bivalent residue derived from optionally substituted thiazole; Y is a bond or lower alkylene; and Z is a group of the formula: or wherein R 2 is a group of the formula: -A-B-D-E-F-G wherein A is a bond or lower alkylene; B is a bond, -NH- or ; D is a bond, -CS- or -CO-; E is a bond or -NH-; F is a bond, -CO-, -O- or -SO 2 -; and G is lower alkyl, optionally protected amino, -OH, phenyl, or ; and R 3 is lower alkyl, provided that when Z is a group of the formula: , then G should not be amino, when Z is a group of the formula: , then G should not be , when Z is a group of the formula: and G is optionally protected amino, then D should be -CS-, or then A should be lower alkylene, B or E should be -NH- and F should be -CO-; or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor as well as a pharmaceutical composition and a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject, and the like.
摘要翻译：式（I）的化合物：U-V-W-X-Y-Z（I）其中U是低级烷基; V是-CONH-或-NR 1 CO-，其中R 1是氢或低级烷基; W是键或低级亚烷基; X是衍生自任选取代的噻唑的二价残基; Y是键或低级亚烷基; 并且Z是下式的基团：或其中R 2是下列基团：-A-B-D-E-F-G其中A是键或低级亚烷基; B是一个键，-NH-或; D是键，-CS-或-CO-; E是键或-NH-; F是键，-CO - ， - O-或-SO 2 - 。且G为低级烷基，任选保护的氨基，-OH，苯基或并且R 3为低级烷基，条件是当Z为下式基团时，则当Z为下式基团时，G不应为氨基，则G不应为 Z是下式的基团：G是任选保护的氨基，则D应为-CS-，或者A应为低级亚烷基，B或E应为-NH-，F应为-CO-; 或其药学上可接受的盐可用作血管粘附蛋白-1（VAP-1）抑制剂，以及用于预防或治疗VAP-1相关疾病，特别是黄斑水肿的药物组合物和方法，该方法包括施用有效的化合物或其药学上可接受的盐对受试者的量等。

5. 发明申请

WO2006011631A3 THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY 审中-公开
公开(公告)号：WO2006011631A3
公开(公告)日：2006-02-02
申请号：PCT/JP2005/014136
申请日：2005-07-27
申请人： ASTELLAS PHARMA INC. , INOUE, Takayuki , TOJO, Takashi , MORITA, Masataka
发明人： INOUE, Takayuki , TOJO, Takashi , MORITA, Masataka
IPC分类号： C07D277/46 , A61K31/426
摘要： A compound of the formula (I), (II), (III) or (IV): wherein each symbol is as defined in the specification,or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject, and the like.

6. 发明申请

WO2004072047A1 INDOLES, BENZIMIDAZOLES OR NAPHHIMIDAZOLES AS HISZONE DEACETYLASE (HDAC) INHIBITOR 审中-公开
标题翻译：吲哚，苯并咪唑或萘啶酮作为HISZONE DEACETYLASE（HDAC）抑制剂
公开(公告)号：WO2004072047A1
公开(公告)日：2004-08-26
申请号：PCT/JP2004/001438
申请日：2004-02-10
申请人： FUJISAWA PHARMACEUTICAL CO., LTD. , URANO, Yasuharu , HOSAKA, Mitsuru , INOUE, Takayuki , OSODA, Kazuhiko , SAWADA, Kozo , KURODA, Akio
发明人： URANO, Yasuharu , HOSAKA, Mitsuru , INOUE, Takayuki , OSODA, Kazuhiko , SAWADA, Kozo , KURODA, Akio
IPC分类号： C07D235/02
CPC分类号： C07D235/14 , C07D209/14 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/12
摘要： A compound of the following formula (I):whereinR¿1? is acyl, R¿2? is hydrogen, orR¿1? and R¿2? are linked together to form a heterocyclic ring, R¿5? is hydroxy, hydroxylamino, lower alkyl, lower alkoxy, halo(lower)alkyl or hydroxy(lower)alkyl, Q is lower alkylene or lower alkenylene, andG is a substituent selected from the following formulas and wherein R¿3? and R¿4? are each independently hydrogen, halogen, halo(lower)alkyl, cyano, aryl or aryl(lower)alkyl optionally substituted with one or more suitable substituent(s), orR¿3? and R¿4? are linked together to form an aromatic ring, andX is NH, O or S, or a salt thereof. The compound is useful as an inhibitor of histone deacetylase.
摘要翻译：下式（I）的化合物：其中R 1是酰基，R 2是是氢，或R 1 和R？连接在一起形成杂环，R 5，羟基，羟基氨基，低级烷基，低级烷氧基，卤代（低级）烷基或羟基（低级）烷基，Q是低级亚烷基或低级亚烯基，G是选自下式的取代基，和R？4？烷基，氰基，芳基或任选被一个或多个合适的取代基取代的芳基（低级）烷基，或R 3' 和R？4？连接在一起形成芳香环，X为NH，O或S，或其盐。该化合物可用作组蛋白脱乙酰酶的抑制剂。

7. 发明申请

WO2004067521A1 THIAZOLE DERIVATIVES AND THEIR USE AS VAP-1 INHIBITORS 审中-公开
标题翻译：噻唑衍生物及其作为VAP-1抑制剂的用途
公开(公告)号：WO2004067521A1
公开(公告)日：2004-08-12
申请号：PCT/JP2004/000708
申请日：2004-01-27
申请人： FUJISAWA PHARMACEUTICAL CO., LTD., , INOUE, Takayuki , TOJO, Takashi , MORITA, Masataka , OHKUBO, Mitsuru , YOSHIHARA, Kousei , NAGASHIMA, Akira
发明人： INOUE, Takayuki , TOJO, Takashi , MORITA, Masataka , OHKUBO, Mitsuru , YOSHIHARA, Kousei , NAGASHIMA, Akira
IPC分类号： C07D277/46
CPC分类号： C07D417/06 , C07D277/46 , C07D277/48 , C07D277/56 , C07D417/12
摘要： A compound of the formula (I): R 1 -NH-X-Y-Z (I) wherein R 1 is acyl; X is a bivalent residue derived from optionally substituted thiazole; Y is a bond, lower alkylene or -COHN-; and Z is a groupe of the formulae (II) or (III) wherein R 2 is a specified substituent or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor for preventing or treating a VAP-1associated disease, especially macular edema.
摘要翻译：式（I）的化合物：其中R 1为酰基的R 1 -NH-X-Y-Z（I） X是衍生自任选取代的噻唑的二价残基; Y是键，低级亚烷基或-COHN-; 并且Z是式（II）或（III）的基团，其中R 2是用作预防或治疗VAP的血管粘附蛋白-1（VAP-1）抑制剂的特定取代基或其药学上可接受的盐 -1相关疾病，特别是黄斑水肿。

8. 发明申请

WO2003082265A2 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING VIRUS INFECTIOUS DISEASES 审中-公开
标题翻译：用于治疗或预防病毒感染性疾病的药物组合物
公开(公告)号：WO2003082265A2
公开(公告)日：2003-10-09
申请号：PCT/JP2003/003929
申请日：2003-03-28
申请人： FUJISAWA PHARMACEUTICAL CO., LTD. , INOUE, Takayuki , MAKI, Katsuyuki , HATAKENAKA, Kazuaki , YAMAGISHI, Yukiko
发明人： INOUE, Takayuki , MAKI, Katsuyuki , HATAKENAKA, Kazuaki , YAMAGISHI, Yukiko
IPC分类号： A61K31/352
CPC分类号： A61K31/055 , A61K31/085 , A61K31/403 , A61K31/404 , A61K31/4184 , A61K31/437 , A61K31/472 , A61K31/517
摘要： This invention provides pharmaceutical compositions for treating or preventing virus infectious diseases, particularly caused by viruses belonging to Flaviviridae family.

9. 发明申请

WO2003057722A3 CYCLIC TETRAPEPTIDE COMPOUND AND USE THEREOF 审中-公开
公开(公告)号：WO2003057722A3
公开(公告)日：2003-07-17
申请号：PCT/JP2002/013754
申请日：2002-12-27
申请人： FUJISAWA PHARMACEUTICAL CO., LTD. , SATOH, Shigeki , URANO, Yasuharu , OSODA, Kazuhiko , HOSAKA, Mitsuru , SAWADA, Kozo , INOUE, Takayuki , MORI, Hiroaki , TAKAGAKI, Shoji , FUJIMURA, Takao , MATSUOKA, Hideaki , YOSHIZAWA, Katsuhiko
发明人： SATOH, Shigeki , URANO, Yasuharu , OSODA, Kazuhiko , HOSAKA, Mitsuru , SAWADA, Kozo , INOUE, Takayuki , MORI, Hiroaki , TAKAGAKI, Shoji , FUJIMURA, Takao , MATSUOKA, Hideaki , YOSHIZAWA, Katsuhiko
IPC分类号： C07K5/12
摘要： A cyclic tetrapeptide compound of the formula (I): wherein R 1 is hydrogen; R 2 is lower alkyl, aryl, optionally substituted ar(lower)alkyl, heterocyclic(lower)alkyl, cyclo(lower)alkyl(lower)alkyl, lower alkylcarbamoyl(lower)alkyl or arylcarbamoyl(lower)alkyl; R 3 and R 4 are each independently hydrogen, lower alkyl, optionally substituted ar(lower)alkyl, optionally substituted heterocyclic(lower)alkyl or cyclo(lower)alkyl(lower)alkyl, or R 3 and R 4 are linked together to form lower alkylene or condensed ring, or one of R 3 and R 4 is linked to the adjacent nitrogen atom to form a ring; R 5 is lower alkylene or lower alkenylene, Y is [wherein R Y1 is hydrogen, halogen or optionally protected hydroxy, R Y2 is hydrogen, halogen, lower alkyl or phenyl, and R Y3 is hydrogen or lower alkyl]; R 8 is hydrogen or lower alkyl; and n is an integer of 1 or 2, or a salt thereof.

10. 发明申请

WO2012036104A1 METHOD FOR MANUFACTURING SEMICONDUCTOR DEVICE 审中-公开
标题翻译：制造半导体器件的方法
公开(公告)号：WO2012036104A1
公开(公告)日：2012-03-22
申请号：PCT/JP2011/070668
申请日：2011-09-05
申请人： SEMICONDUCTOR ENERGY LABORATORY CO., LTD. , YAMAZAKI, Shunpei , NONAKA, Yusuke , INOUE, Takayuki , TSUBUKU, Masashi , AKIMOTO, Kengo , MIYANAGA, Akiharu
发明人： YAMAZAKI, Shunpei , NONAKA, Yusuke , INOUE, Takayuki , TSUBUKU, Masashi , AKIMOTO, Kengo , MIYANAGA, Akiharu
IPC分类号： H01L21/336 , H01L21/20 , H01L21/203 , H01L29/786
CPC分类号： H01L29/78606 , H01L23/552 , H01L23/564 , H01L29/04 , H01L29/66969 , H01L29/7869 , H01L29/78696 , H01L2924/0002 , H01L2924/00
摘要： An object is to manufacture a semiconductor device including an oxide semiconductor film, which has stable electric characteristics and high reliability. A crystalline oxide semiconductor film is formed, without performing a plurality of steps, as follows: by utilizing a difference in atomic weight of plural kinds of atoms included in an oxide semiconductor target, zinc with low atomic weight is preferentially deposited on an oxide insulating film to form a seed crystal including zinc; and tin, indium, or the like with high atomic weight is deposited on the seed crystal while causing crystal growth. Further, a crystalline oxide semiconductor film is formed by causing crystal growth using a seed crystal with a hexagonal crystal structure including zinc as a nucleus, whereby a single crystal oxide semiconductor film or a substantially single crystal oxide semiconductor film is formed.
摘要翻译：本发明的目的是制造具有稳定的电特性和高可靠性的氧化物半导体膜的半导体装置。通过利用包含在氧化物半导体靶中的多种原子的原子量的差异，形成结晶氧化物半导体膜，而不进行多个步骤，优选将低原子量的锌沉积在氧化物绝缘膜上形成包含锌的晶种; 并且具有高原子量的锡，铟等沉积在晶种上同时引起晶体生长。此外，通过使用具有包含锌作为核的六方晶系结构的晶种引起晶体生长而形成结晶氧化物半导体膜，由此形成单晶氧化物半导体膜或基本上单晶氧化物半导体膜。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式